BR112014020345A2 - Medicamentos antivirais para o tratamento da infecção por arenavírus - Google Patents
Medicamentos antivirais para o tratamento da infecção por arenavírusInfo
- Publication number
- BR112014020345A2 BR112014020345A2 BR112014020345A BR112014020345A BR112014020345A2 BR 112014020345 A2 BR112014020345 A2 BR 112014020345A2 BR 112014020345 A BR112014020345 A BR 112014020345A BR 112014020345 A BR112014020345 A BR 112014020345A BR 112014020345 A2 BR112014020345 A2 BR 112014020345A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- antiviral drugs
- arenavirus infection
- arenavirus
- infection
- Prior art date
Links
- 208000005989 Arenaviridae Infections Diseases 0.000 title 1
- 239000003443 antiviral agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600036P | 2012-02-17 | 2012-02-17 | |
| US61/600,036 | 2012-02-17 | ||
| PCT/US2013/026173 WO2013123215A2 (en) | 2012-02-17 | 2013-02-14 | Antiviral drugs for treatment of arenavirus infection |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112014020345A2 true BR112014020345A2 (pt) | 2017-06-20 |
| BR112014020345A8 BR112014020345A8 (pt) | 2021-07-06 |
| BR112014020345B1 BR112014020345B1 (pt) | 2021-09-21 |
Family
ID=48984889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014020345-8A BR112014020345B1 (pt) | 2012-02-17 | 2013-02-14 | Composto antiviral, composição farmacêutica compreendendo dito composto e uso dos mesmos para tratar infecção viral ou doença associada à mesma |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9498470B2 (pt) |
| EP (1) | EP2814486B8 (pt) |
| JP (1) | JP6200903B2 (pt) |
| KR (1) | KR101893632B1 (pt) |
| CN (3) | CN110698408B (pt) |
| AP (1) | AP3675A (pt) |
| AU (2) | AU2013221475B2 (pt) |
| BR (1) | BR112014020345B1 (pt) |
| CA (1) | CA2864484C (pt) |
| HK (1) | HK1204949A1 (pt) |
| IL (2) | IL234091A (pt) |
| MX (1) | MX359989B (pt) |
| SG (1) | SG11201404898RA (pt) |
| WO (1) | WO2013123215A2 (pt) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101652577B1 (ko) * | 2013-04-19 | 2016-08-30 | 영남대학교 산학협력단 | 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염 및 이를 유효성분으로 함유하는 혈관신생으로 인한 질환의 예방 또는 치료용 약학조성물 |
| WO2018013430A2 (en) * | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| TWI771319B (zh) | 2016-09-09 | 2022-07-21 | 美商英塞特公司 | 吡唑并吡啶化合物及其用途 |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
| PT3755703T (pt) | 2018-02-20 | 2022-08-16 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida e compostos relacionados como inibidores de hpk1 para o tratamento do cancro |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| AR117228A1 (es) * | 2018-12-06 | 2021-07-21 | Arisan Therapeutics | DERIVADOS DE PIRAZOLO[1,2-a]PIRIDINA, 1H-BENZO[d][1,2,3]TRIAZOL, IMIDAZOPIRIMIDINA Y BENCIMIDAZOL PARA USAR EN EL TRATAMIENTO DE LA INFECCIÓN POR ARENAVIRUS |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| TW202114680A (zh) | 2019-08-06 | 2021-04-16 | 美商英塞特公司 | Ｈｐｋ１抑制劑之固體形式 |
| CA3150681A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| AU2020364007A1 (en) | 2019-10-11 | 2022-04-28 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN113214161A (zh) * | 2021-02-05 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种具有抗拉沙病毒活性的化合物及其制备方法和应用 |
| CN113234022A (zh) * | 2021-02-05 | 2021-08-10 | 中国人民解放军军事科学院军事医学研究院军事认知与脑科学研究所 | 一种苯并咪唑类衍生物及其合成方法和应用 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| JPS63157157A (ja) * | 1986-12-22 | 1988-06-30 | Canon Inc | 電子写真感光体 |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| DE3928177A1 (de) * | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JPH0446352A (ja) * | 1990-06-14 | 1992-02-17 | Minolta Camera Co Ltd | 感光体 |
| US5554630A (en) * | 1993-03-24 | 1996-09-10 | Neurosearch A/S | Benzimidazole compounds |
| AU675484B2 (en) * | 1993-03-24 | 1997-02-06 | Neurosearch A/S | Benzimidazole compounds, their use and preparation |
| AU7275894A (en) * | 1993-08-04 | 1995-02-28 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazolylalkylamine derivative and pharmaceutical composition thereof |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DK1246808T3 (da) * | 2000-01-14 | 2011-12-05 | Bayer Pharma AG | 1,2-diarylbenzimidazoler til behandling af sygdomme, som er associeret med en mikroglia-aktivering |
| ES2310202T3 (es) * | 2001-04-26 | 2009-01-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo. |
| FR2851248B1 (fr) * | 2003-02-18 | 2005-04-08 | Aventis Pharma Sa | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
| WO2005080380A1 (en) * | 2004-02-03 | 2005-09-01 | Eli Lilly And Company | Kinase inhibitors |
| DE102005012875B4 (de) * | 2005-03-19 | 2006-11-16 | Sanofi-Aventis Deutschland Gmbh | Verwendung von Amino substituierten 8-N-Benzimidazolen |
| US7977365B2 (en) * | 2006-03-02 | 2011-07-12 | Siga Technologies, Inc. | Antiviral drugs for treatment of arenavirus infection |
| JP5380078B2 (ja) * | 2006-03-02 | 2014-01-08 | サイガ・テクノロジーズ・インコーポレーテッド | アレナウイルス感染の治療のための抗ウイルス薬剤 |
| US7999001B2 (en) * | 2007-01-15 | 2011-08-16 | The United States Of America As Represented By The Secretary Of The Army | Antiviral compounds and methods of using thereof |
| JP5393679B2 (ja) | 2007-08-27 | 2014-01-22 | シガ・テクノロジーズ・インコーポレーテッド | アレナウイルス感染症を治療するための抗ウイルス薬 |
| US8507473B2 (en) * | 2008-09-11 | 2013-08-13 | Arena Pharmaceuticals, Inc. | 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders |
| CN102256972A (zh) * | 2008-12-18 | 2011-11-23 | 霍夫曼-拉罗奇有限公司 | 噻唑基-苯并咪唑类 |
| WO2011063293A1 (en) * | 2009-11-20 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antihelminth agents |
-
2013
- 2013-02-14 SG SG11201404898RA patent/SG11201404898RA/en unknown
- 2013-02-14 CN CN201910977855.2A patent/CN110698408B/zh active Active
- 2013-02-14 MX MX2014009931A patent/MX359989B/es active IP Right Grant
- 2013-02-14 AP AP2014007925A patent/AP3675A/xx active
- 2013-02-14 US US14/379,028 patent/US9498470B2/en active Active
- 2013-02-14 CN CN201380019936.2A patent/CN104507473A/zh active Pending
- 2013-02-14 CA CA2864484A patent/CA2864484C/en active Active
- 2013-02-14 CN CN201910977868.XA patent/CN110776453A/zh active Pending
- 2013-02-14 KR KR1020147025954A patent/KR101893632B1/ko active IP Right Grant
- 2013-02-14 JP JP2014557773A patent/JP6200903B2/ja active Active
- 2013-02-14 AU AU2013221475A patent/AU2013221475B2/en not_active Ceased
- 2013-02-14 EP EP13749809.3A patent/EP2814486B8/en active Active
- 2013-02-14 BR BR112014020345-8A patent/BR112014020345B1/pt not_active IP Right Cessation
- 2013-02-14 WO PCT/US2013/026173 patent/WO2013123215A2/en active Application Filing
-
2014
- 2014-08-13 IL IL234091A patent/IL234091A/en active IP Right Grant
-
2015
- 2015-06-15 HK HK15105630.8A patent/HK1204949A1/xx not_active IP Right Cessation
-
2016
- 2016-11-16 US US15/353,351 patent/US10000486B2/en active Active
-
2017
- 2017-01-18 AU AU2017200346A patent/AU2017200346B2/en not_active Ceased
- 2017-03-22 IL IL251327A patent/IL251327B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014020345A2 (pt) | Medicamentos antivirais para o tratamento da infecção por arenavírus | |
| BR112015002524A2 (pt) | derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças. | |
| CO7061081A2 (es) | Derivados macrocíclicos para el tratamiento de enfermedades | |
| BR112016009485A2 (pt) | Inalador de medicamento | |
| DK3608325T3 (da) | Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse | |
| DK3639872T3 (da) | Lægemiddeladministrationsanordning | |
| BR112015003345A2 (pt) | protocolo pandêmico para atendimento de emergência | |
| DK2931296T3 (da) | Sygdomsbehandling, der involverer mucin | |
| DK3357522T3 (da) | Coatet medicinsk genstand til lægemiddelsfrigivelse | |
| DK2900259T3 (da) | Glycosidase-regime til behandling af infektionssygdomme | |
| DK2854765T3 (da) | Farmaceutisk pemetrexed-opløsning | |
| PL2939665T3 (pl) | Kompozycja farmaceutyczna do leczenia zakażeń hiv | |
| DK2897681T3 (da) | Medicinsk applikator | |
| BR302013000073S1 (pt) | Configuração aplicada em artigo médico | |
| DK2825636T3 (da) | Behandling af sædceller | |
| SMT201600268B (it) | Composizione per il trattamento delle neuropatie | |
| DK2694056T3 (da) | Terapeutisk behandling | |
| FR2999159B1 (fr) | Blister de broche medicale | |
| BR302012003979S1 (pt) | Configuração aplicada em fármaco | |
| PL395785A1 (pl) | Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu | |
| UA24885S (uk) | Карта-калькулятор дозувань медичних препаратів | |
| CO6990714A2 (es) | Composicíones farmacéuticas que comprenden cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales | |
| UA24520S (uk) | Шприц медичний | |
| UA24471S (uk) | Шприц медичний | |
| UA24469S (uk) | Шприц медичний |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 11A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2761 DE 05-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |